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ABSTRACT 
Objective: The prior objective of the current research work was to develop once-daily levetiracetam extended/controlled-release tablets having 
zero-order release kinetics with the plastic matrix as the release retarding element. For a high water-soluble drug, the formulation of a dosage form 
so as to have an extended drug release has always been a difficult task.  
Methods: In the current work, levetiracetam which is a highly soluble drug was taken as the model drug for which extended-release matrix tablets 
were developed using varied plastic polymers like Polyvinyl acetate (PVAc), Polyvinyl chloride (PVC), Eudragit RSPO and Eudragit RLPO. PVP was 
considered as a pore-forming agent and PEG 6000 was taken as a water regulating agent. The porous plastic matrix tablets were prepared by 
embedding the drug in solvent-activated polymer dispersion followed by drying, sieving, mixing with other excipients and finally compressed. 
Including physical characterization studies and drug release studies, the tablets were subjected to SEM studies before and after the dissolution 
studies to analyze the effect of the pore former.  
Results: Pre-compression mixtures exhibited good packageability of 81-92% and hence the compressed tablets were strong enough with good 
tensile strength in the range of 0.78–0.90 N/mm2
Conclusion: The levetiracetam porous plastic matrix tablets were developed with zero-order drug release that was effectively controlled for 24hr. 
. Drug release study results showed that the drug release was controlled for a period of 12–24h. 
PVAc had shown better controlled-release among all the plastic polymers taken. PEG 6000 in combination with PVP produced the desired zero-
order drug release.  
Keywords: Porous plastic matrix, Pore former, Highlysoluble drugs, Zero-order controlled release, Embedding 
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INTRODUCTION 
Developing once-daily controlled-release tablets is highly beneficial 
to the patient in terms of convenience of administration and reduced 
dosing frequency. Further, obtaining constant zero-order drug 
release from such tablets maintains the plasma drug concentrations 
in a constant manner so that tissue sensitivity is protected. 
Development of such dosage forms for drugs with high solubility and 
high dose has always been a challenge. Drugs with high solubility as 
well as high dose require a high amount of polymer for achieving 
controlled release which may greatly increase the final weight of the 
tablet thus causing difficulty in swallowing. Though several 
technologies like different matrix and reservoir systems [1-3] have 
been investigated to address this challenge, still there is a significant 
scope to investigate further especially by employing highly 
hydrophobic polymers like plastic matrices [4-6]. Adequate 
literature published the use of plastic polymers like Eudrgait and 
other hydrophobic matrices to attain the controlled release drug 
release some of them include were by Apurba Sarker Apu et al. [7]; 
H Tabandeh et al. [8]; Sarika Pundir et al. [9]; and Sudarshan Singh 
et al. [10]. But, in all this literature works the final weight of the 
tablets were more than 1000 mg and also drug release was 
completed well before 24 h. Hence, there is a need to develop 
controlled release matrix tablets for drugs with a high dose to 
prolong the drug release for 24 h and also to restrict the final weight 
of the tablet. 
Levetiracetam (LVT) is a BCS Class I drug possessing high solubility 
of 1040 mg/ml and of 1000 mg as starting dose used in the 
treatment of epilepsy [11]. The high dose as well as high solubility of 
LVT resulting in the formulation of a larger size tablet is a major 
drawback of the formulation of this drug. Hence, LVT is selected as 
the model drug in this research work, so as to overcome these 
problems associated with the formulation. 
Hence, in the current research, it was aimed to develop once daily 
controlled release matrix tablets of possible less final weight/size 
with constant zero-order drug release for a high water-soluble and 
high dose drug by taking Levetiracetam as a model drug. This was 
further aimed to achieve by using plastic matrices viz. Eudragit 
RSPO, Eudragit RLPO, polyvinyl acetate and polyvinyl chloride 
combined with a pore former PVP K15 [12] and water regulating 
agent PEG 6000 regarding which a very little literature suggested 
the possibility of their exploration for developing controlled release 
porous matrix tablets with the zero-order release.  
MATERIALS AND METHODS 
Materials 
The API, Levetiracetam was obtained as a gift sample from Hetero 
Drugs Pvt. Ltd., Hyderabad; polyvinyl acetate, polyvinyl chloride, 
Eudragit RLPO and RSPO, PVP K15 (low viscosity grade) and PEG 
6000 were procured from Sigma Aldrich, Mumbai; Magnesium 
stearate and talc were procured from Loba Chemie Ltd, 
Hyderabad. 
Drug-excipient compatibility studies 
Fourier Transform Infrared (FT-IR) spectroscopy was used to 
study the compatibility between LVT and the polymers. Pure 
LVT and mixtures of LVT with the polymers at maximum weight 
ratios as per the formulae were prepared as pellets in a 
hydraulic press after mixing with KBr. In a wavelength range of 
400 to 4000 cm-1
Preparation of plastic matrix tablets of LVT 
, each pellet was studied by FT-IR spectroscopy 
and an average of 16 scans of the spectrum was taken. The pure 
drug spectrum was then compared with the spectrum of the 
physical mixtures. 
As per the formulae (table 1), required quantities of plastic polymers 
were dissolved in acetone to attain a dispersion with semisolid 
consistency. Pre-determined quantity of LVT and PG 6000 were 
embedded [13] in the above mixture with vigorous mixing which 
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was then subjected to drying. This LVT embedded plastic dispersion 
was sieved through #20 sieve to obtain plastic matrix granules 
which are further mixed with PVP K15, magnesium stearate and talc. 
The blend was then compressed using 12 mm punch to obtain flat-
faced round elegant tablets [14]. 
Characterization studies for the pre-compression mixture 
The plastic matrix granules of all the formulations were subjected to 
different evaluation studies [10] viz. bulk density, tapped density, 
Carr’s index, Hausner’s ratio and angle of repose in order to assure 
their suitability for compression into tablets. 
Characterization studies for the compressed plastic matrix 
tablets of LVT 
Tensile strength 
The tensile strength is the stress required to break a tablet indicating 
the tablet’s physical strength. Vernier caliper was used to measure the 
thickness (t) and diameter (D) of the tablet. Monsanto hardness tester 
was used to determine the hardness or crushing strength (Fc
 
). Tensile 





Table 1: Compositions of various formulations of porous plastic matrix tablets of LVT 































Levetiracetam 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 
Eudragit RLPO 150 150 150 200 - - - - - - - - - - - - 
Eudragit RSPO  - - - - 150 150 150 200 - - - - - - - - 
Polyvinyl 
acetate  
- - - - - - - - 150 150 150 200 - - - - 
Polyvinyl 
chloride  
- - - - - - - - - - - - 150 150 150 200 
PEG 6000 - 50 60 - - 50 60 - - 50 60 - - 50 60 - 
PVP 75 25 15 25 75 25 15 25 75 25 15 25 75 25 15 25 
Lubricant 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 
Glidant 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 
Total 745 745 745 745 745 745 745 745 745 745 745 745 745 745 745 745 
 
Packing fraction and porosity 
The degree of consolidation of tableting powder after compression 






where w is the weight of tablet; r and t are radius and thickness of 
the tablet; and ρ is the true density of the tableting powder. Liquid 
displacement method using liquid paraffin was used to determine 
the true density of the tableting powder. The porosity indicates the 
degree of penetration of water into the tablet which is obtained by 
subtracting the packing fraction form 1. 
Friability 
Roche friabilator was used to determine the friability [17] in which 
10 tablets were rotated at a speed of 25 rpm for 4 min. so as to 
complete 100 revolutions. The tablets were then removed, dedusted 
and weighed. From the combined weights of tablets before (w1) and 
after (w2
Drug content 





100 mg drug equivalent powder of the tablets powder was taken 
and added into water (as the LVT is freely water-soluble) and 
subjected to intense mixing ensuring dissolution of LVT. The mixture 
was then filtered and diluted in a 100 ml volumetric flask. After 
necessary dilutions, the filtrate was analyzed using a UV-Visible 
spectrophotometer at its maximum wavelength of 194 nm [18]. 
Drug release studies 
The prepared LVT plastic matrix tablets were subjected to drug 
release studies according to the USFDA specified dissolution 
conditions [16]. In basket (USP type I) apparatus at 100 rpm, 900 ml 
of 0.05M phosphate buffer pH 6.0 was taken as the dissolution 
medium. At various time intervals, 5 ml of samples were taken and 
replaced with fresh buffer. After suitable dilutions, the collected 
samples were analyzed at a maximum wavelength of 194 nm using a 
UV-Visible spectrophotometer. 
Drug release kinetic studies 
To determine the order of drug release kinetics and the mechanism 
of drug release from the developed LVT plastic matrix tablets, the 
data obtained from the drug release studies were fitted to various 
kinetic models [19]. Zero-order, first-order, Higuchi’s and 
Korsmeyer-Peppas models the kinetic models employed to fit the 
data were. 
SEM studies 
The surface morphology of the formulated tablet was observed 
before and after subjecting to the drug release studies by carrying 
the scanning electron microscopy studies [19] to assess the 
effectiveness of the pore former used. 
Statistical analysis 
Different formulation variables were viz. type of plastic polymer, 
amount of the polymer, amount of pore former so as to achieve 
constant drug release for 24 h. The results of drug release studies 
were subjected to ANOVA test to investigate whether the effect of 
different formulation variables taken in this work on drug release 
rate was significant or not. 
RESULTS AND DISCUSSION 
Drug-excipient compatibility studies 
The IR spectrum of pure LVT was compared with the spectra of its 
physical mixtures with the selected plastic materials (shown in fig. 
1). The characteristic peaks corresponding to the characteristic 
functional groups of LVT observed in the spectrum of the pure drug 
were N-H stretching at 3359 cm-1; C-H stretching at 2895 cm-1; C=O 
bending at 1674 cm-1; C-H bending at 1430 cm-1; C-N stretching at 
1084 cm-1 [16]. The same peaks at and close to these wavenumbers 
were also observed in the spectra of physical mixtures of LVT with 
all the polymers. This indicated the absence of incompatibilities 
between LVT and the selected plastic polymers, PVP K15 and PEG 
6000 thus permitting their use in LVT plastic matrix tablets. 
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Fig. 1: FT-IR spectra of pure LVT and physical mixtures of LVT with different polymers. (a) Pure LVT; (b) LVT+Eudragit RLPO; (c) 
LVT+Eudragit RLPO; (d) LVT+PVAc; (e) LVT+PVC; (f) LVT+PVP and (g) LVT+PEG 6000 
 
Characterization studies for the pre-compression mixture 
Prior to tapping, the bulk density of all the formulations was found 
to be in the range of 0.50-0.52 g/ml and after tapping, it was found 
to be in the range of 0.57-0.60 g/ml. A good compressibility and 
package ability for table ting of the plastic matrix granules has been 
inferred from the difference in bulk densities before and after 
tapping. A range of 1.16-1.13 and 13.56-11.48 were observed for the 
Hausner’s ratio and Carr’s index respectively. Angle of repose values 
were found to be in the range of 12.51-14.76 °and all the results 
indicated good to excellent flow properties and hence could be 
effectively compressed into tablets. 
Preparation of plastic matrix tablets of LVT 
The plastic matrix tablets were prepared by dispersing the drug and 
PEG 6000 mixture into Eudragit RLPO/Eudragit RSPO/PVAc/PVC 
matrix followed by mixing with PVP K15 and other excipients and 
finally compressed into flat-faced tablets of 12 mm diameter. The 
embedment of the drug into the solvent-activated plastic matrix made 
effective incorporation of the drug into the matrix would result in 
relatively less amount of rate retardant material sufficient to achieve 
desired control release when compared to simple physical mixing of 
drug and polymer. This would reduce the weight of the final tablet, 
which is the prior and substantial advantage especially for high-dose 
drugs like LVT. 
Physical characterization studies 
Tensile strength 
All the formulations of the LVT plastic matrix tablets were 
compressed using punches of 12 mm diameter and an adjusted 
thickness of 5.5 mm. The compressed tablets were found to have 
hardness in the range of 8.2-9.5 kilogram-force (kgf), therefore 
showing the tensile strength values in the range of 0.78-0.90 N/mm2 
as shown in the table 2. The high hardness and tensile strength 
values obtained indicated the good physical strength of tablets and 
the selected plastic polymers and their mode of use for the 
development of matrix tablets. 
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Packing fraction 
The packing fraction is dependent on the nature of the material to be 
compressed besides particle size. The higher packing fraction 
indicates greater efficiency of tableting and thereby greater strength 
of the tablets [15]. The values of this packing fraction for all the 
formulations of plastic matrix tablets of LVT were found to be in the 
range of 0.81-0.92indicating that all the formulations had good 
tableting efficiency thus suitable for compression into tablets. The 
residual porosity of the tablets was obtained by subtracting the 
packing fraction from 1 and these values are ranging from 0.08-0.19 
(table 2). This little porosity is necessary for enabling the drug 
release from the plastic matrix tablets by penetration of water. 
Friability 
Friability gives the needed evidence for the strength of plastic 
matrix tablets. The % friability values for all the formulation varied 
in the range of 0.40-0.52% (table 2). The obtained values indicated 
the developed tablets were adequately strong to overcome the 
forces that might occur during handling, packing and transportation. 
Drug release studies 
The prepared LVT plastic matrix tablets of LVT were subjected to 
drug release studies according to USFDA dissolution specifications. 
The dissolution profiles in the form of zero-order plots for tablets of 
all plastics were shown in fig. 2 to fig. 5. 
 
Table 2: Results of different physical characterization studies of porous plastic matrix tablets of LVT 
S. No. Formulation Tensile strength (N/mm2 Packing fraction (P) f Porosity fraction (1–P) f Friability (%) ) 
1 ERLF1 0.85±0.01 0.83±0.01 0.17±0.02 0.51±0.02 
2 ERLF2 0.87±0.03 0.88±0.02 0.12±0.03 0.46±0.05 
3 ERLF3 0.89±0.02 0.86±0.03 0.14±0.01 0.56±0.04 
4 ERLF4 0.88±0.03 0.91±0.01 0.09±0.03 0.52±0.03 
5 ERSF1 0.82±0.01 0.84±0.03 0.16±0.04 0.54±0.05 
6 ERSF2 0.85±0.02 0.89±0.02 0.11±0.02 0.47±0.04 
7 ERSF3 0.87±0.01 0.86±0.04 0.14±0.03 0.50±0.02 
8 ERSF4 0.80±0.02 0.90±0.03 0.10±0.01 0.42±0.06 
9 PVAcF1 0.85±0.03 0.83±0.02 0.17±0.01 0.46±0.04 
10 PVAcF2 0.83±0.02 0.82±0.01 0.18±0.02 0.45±0.02 
11 PVAcF3 0.82±0.03 0.90±0.01 0.10±0.02 0.44±0.03 
12 PVAcF4 0.80±0.01 0.81±0.02 0.09±0.04 0.42±0.05 
13 PVCF1 0.79±0.01 0.85±0.03 0.15±0.03 0.48±0.02 
14 PVCF2 0.81±0.02 0.92±0.02 0.18±0.03 0.45±0.03 
15 PVCF3 0.84±0.03 0.91±0.01 0.09±0.02 0.41±0.04 
16 PVCF4 0.80±0.02 0.87±0.03 0.13±0.01 0.44±0.05 
*
 
Results are expressed in Avg.±standard deviation for three trials 
 
Fig. 2: Zero-order plots of drug release of tablets prepared with eudragit RLPO 
 
 
Fig. 3: Zero-order plots of drug release of tablets prepared with Eudragit RSPO 
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Fig. 4: Zero-order plots of drug release of tablets prepared with Polyvinyl chloride 
 
 
Fig. 5: Zero-order plots of drug release of tablets prepared with polyvinyl acetate 
 
In the formulation of plastic matrix tablets, the materials responsible 
for drug release were plastic polymers, PEG 6000 and PVP K15. The 
plastic polymers are highly hydrophobic and have a very low water 
permeability favoring the controlled release of the drug. PEG 6000 is 
a hydrophilic and slowly soluble polymer that effectively regulates 
the availability of water inside the plastic matrix. PVP K15 is a low 
viscous, highly and readily water-soluble material thereby readily 
dissolved when added to the dissolution medium forming pores on 
the plastic matrix tablet favoring the drug release. 
After several trials of each plastic polymer, four formulations were 
developed in order to study the effect of amounts of plastic polymer, 
PEG 6000 and PVP. The first three formulations containing 150 mg 
and the fourth formulation containing 250 mg of plastic with varying 
amounts of PEG 6000 and PVP. The effect of the amounts of plastic 
and PVP without the influence of PEG 6000, for every plastic 
polymer taken, can be understood by comparing formulations F1 
and F4. The effect of PEG 6000 can be understood by comparing 
formulations F2 and F3. 
 
Table 3: Results of drug release kinetic studies of porous plastic matrix tablets of LVT 
S. No. Formulation Regression (R2 Zero-order rate 
constant (%/h) 
) values First-order rate 
constant (h-1
Peppas ‘n’ 
values ) Zero-order First-order Higuchi’s 
1 ERLF1 0.715 0.958 0.986 -- 0.295 0.597 
2 ERLF2 0.971 0.77 0.918 6.707 -- 0.771 
3 ERLF3 0.99 0.975 0.887 6.17 -- 0.851 
4 ERLF4 0.695 0.997 0.989 -- 0.2 0.576 
5 ERSF1 0.566 0.973 0.966 -- 0.237 0.58 
6 ERSF2 0.991 0.839 0.883 6.143 -- 0.839 
7 ERSF3 0.986 0.748 0.89 5.043 -- 0.763 
8 ERSF4 0.646 0.996 0.979 -- 0.18 0.577 
9 PVAcF1 0.675 0.996 0.97 -- 0.148 0.619 
10 PVAcF2 0.987 0.878 0.896 4.867 -- 0.794 
11 PVAcF3 0.996 0.933 0.87 4.118 -- 0.878 
12 PVAcF4 0.768 0.996 0.973 -- 0.122 0.689 
13 PVCF1 0.662 0.997 0.979 -- 0.184 0.599 
14 PVCF2 0.985 0.759 0.898 5.32 -- 0.774 
15 PVCF3 0.994 0.951 0.847 4.504 -- 0.81 
16 PVCF4 0.685 0.991 0.981 -- 0.152 0.607 
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Effect of type of plastic polymer 
The efficiency of plastic polymers taken in this research work to 
control the release of drug was found to be highest for Eudragit 
RLPO and lowest for polyvinyl acetate in the order of Eudragit 
RLPO>Eudragit RSPO>Polyvinylchloride>Polyvinyl acetate. The 
effect of type of plastic polymer on the drug release rate was found 
to be significant (p<0.05, one-way ANOVA). The rate constant values 
were showed in the table 3. This could be attributed to the degree of 
permeability of water by the polymer into the plastic polymer 
matrix [21-23]. With the increase in the permeability of water into 
the plastic matrix, the diffusion of the drug from the plastic matrix 
increases and vice versa.  
Effect of amount of plastic polymers 
It was evident from the formulations F1 and F4 that with the 
increase in the concentration of the plastic polymer, the drug release 
rate was found to be significantly decreased (p<0.05, one-way 
ANOVA) due to the increase in the density of the plastic polymer as 
well as owing to the difficulty in permeation of water into the plastic 
matrix at high amounts of the matrix polymers. The obtained results 
were correlated with those reported by Maskova E et al. [23]. 
Effect of amount of PEG 6000 
A significant effect of PEG was found on the drug release rate 
(p<0.05, one-way ANOVA) and also the drug release kinetics (table 
3). In case of every plastic polymer, formulations without PEG 6000 
in F1 and F4 have shown first-order kinetics of drug release and F2 
and F3 containing PEG 6000 have shown zero-order drug release 
kinetics. This could be attributed to the ability of PEG 6000 to 
maintain the availability of water inside the matrix constantly that 
could alter the drug release [24, 25] and the insoluble, non-swellable 
as well as non-erodible plastic matrix could maintain the constant 
geometry of the tablet achieved constant zero-order drug release. 
Effect of amount of PVP K15 
PVP K15 was employed in this study as a pore former which allows 
access of water into the plastic matrix tablet upon its addition into 
aqueous medium and hence drug release would be started without 
much lag time. The amount of PVP K15 showed a significant (p<0.05, 
one-way ANOVA) effect on drug release by comparing the 
formulations F1 and F4 as well as F2 and F3 in the case of every plastic 
matrix. The higher amount of PVP K15 in in F1 made the drug release 
rapid when compared to that of F4. Similarly, formulation F2 showed 
higher release rate when compared to that of F3, which could be 
attributed to the presence of higher amount of PVP K15 in F2 than in 
F3. High amount of poreformer PVP could create more pores in the 
plastic matrix tablet which could permeate more amount of water thus 
allowing more amount of drug release [26, 27]. 
This amount of pore former along with PEG 6000 was found to be 
critical in identifying the formulation with desired drug release profile. 
Formulations F2 and F3 in case of every plastic polymer showed zero-
order drug release and the release was more controlled in case of F3 
formulations when compared to those of F2 formulations. Further, 
formulation F2 with relatively less amount of PEG 6000 and more 
amount of pore former could show a maximum control of drug release 
up to 20 hr only which was in case of PVAc matrix. Whereas 
formulation F3 in case of PVAc showed constant zero-order drug 
release up to 24 hr and hence the set objective of the work was 
achieved by this porous matrix tablets of formulation PVAcF3. 
Drug release kinetic studies 
The Higuchi’s and Korsmeyer-Peppas plots were used to study the 
mechanism of drug release and the results were shown in table 3. In 
every plastic polymer, the formulations, F1 and F4 have shown more 
Higuchi’s regression values and lesser Korsemeyer-Peppas 
coefficients than those of their corresponding F2 and F3 
formulations. This elucidated that the drug release was majorly by 
diffusion in F1 and F4 formulations. Whereas, in case of F2 and F3 
formulations, higher Korsemeyer-Peppas coefficients and low 
Higuchi’s regression values indicated thenon-Fickiandiffusion of 
drug release that is diffusion by boundary effect and pores. This 
could be attributed to the presence of PEG 6000 in the formulations 
F2 and F3. During the time of drug release, zero-order release from 
these F2 and F3 formulations was obtained as the boundary effect 
and pores were constant. 
SEM studies 
The porous structure of the matrix tablet (of formulation PVAcF3) 
after drug release study was observed in comparison with the tablet 
surface before subjecting to the drug release study by SEM studies 
(fig. 6). The results of SEM studies clearly illustrated the formation 
of pores which might be because of the pore former PVP K15, which 
could modify the permeability of water into the matrix thus aid in 
achieving desired drug release profile. 
 
 
Fig. 6: SEM images of porous plastic matrix tablets (a) Before drug release study (b) After drug release study 
 
CONCLUSION 
This work was carried to develop a single daily dose, controlled 
release tablet of LVT with constant zero-order drug release and also 
with minimum possible final weight. With variable amounts of PEG 
6000 as water content regulator and PVP as pore former in the 
matrix, the LVT plastic matrix tablets were developed. A zero-order 
release of drug from the plastic matrix tablets can be obtained in 
tablets with PEG 6000 i.e. formulations F2 and F3 in the case of each 
plastic polymer. The drug release from the plastic matrix tablets was 
found to follow zero-order release and controlled for 24 h in the 
case of PVAc matrix which was found to be more effective among all 
the studied polymers in this study and also when compared to the 
Levetiracetum tablets prepared by Sudarshan Singh et al. [12] 
whose drug release was controlled for about 18 h only and also the 
final weight of the tablet was 1100 mg. which was very higher than 
the final weight of 745 mg in the current study. Hence, the desired 
zero-order control release with high release retardation and lower 
weight of the final tablet has been achieved successfully through the 
formulation of porous plastic matrix tablets in this research work. 
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